Stocktoria
Cue Biopharma, Inc. CUE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-01-02
Cue Biopharma, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -96.7% | -446.9% | -949.9% | -4275.1% | -292.6% |
| Net margin | -96.9% | -438.0% | -924.1% | -4257.8% | -295.6% |
| FCF margin | -79.6% | -391.9% | -727.9% | -3371.6% | -266.0% |
| Return on assets | -63.0% | -126.4% | -82.5% | -58.1% | -53.0% |
| Return on equity | -100.6% | -232.4% | -136.8% | -80.7% | -67.4% |
| Debt / equity | — | 0.00× | 0.11× | 0.12× | 0.00× |
| Current ratio | 2.74 | 1.84 | 3.01 | 6.68 | 5.35 |
| Revenue growth | 195.7% | 69.2% | 341.0% | -91.7% | 373.7% |
Source: SEC EDGAR filings · CIK 0001645460 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.